p53 Gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma

C. Lavarino, S. Pilotti, M. Oggionni, L. Gatti, P. Perego, G. Bresciani, M. A. Pierotti, G. Scambia, G. Ferrandina, A. Fagotti, C. Mangioni, V. Lucchini, F. Vecchione, G. Bolis, G. Scarfone, F. Zunino

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

Purpose: The p53 gene plays a critical role in cellular response to DNA damage and has been implicated in the response to platinum compounds in ovarian carcinoma patients. Because taxanes could induce p53-independent apoptosis, we assessed the relevance of p53 gene status to response in ovarian carcinoma patients receiving paclitaxel and platinum-containing chemotherapy. Patients and Methods: Forty-eight previously untreated patients with advanced disease received standard paclitaxel/platinum-based chemotherapy. In tumor specimens collected at the time of initial surgery, before therapy, p53 gene status and expression were examined by single-strand conformation polymorphism, sequence analysis, and immunohistochemical analysis. Microsatellite instability analysis was performed on available samples from 30 patients. Results: Thirty-four (71%) of the 48 patients had a clinical response. Pathologic complete remission was documented in 13 (27%) of 48 patients. p53 mutations were detected in 29 (60%) of 48 tumors. Among the patients with mutant p53 tumors, 25 patients (86%) responded to chemotherapy. Only nine (47%) of 19 patients with wild-type p53 tumors responded to the same treatment. The overall response rate and the complete remission rate were significantly higher among patients with mutant p53 tumors than among patients with wild-type p53 tumors (P = .008). Most of the tested tumors not associated with complete remission (10 of 12 tumors) were also characterized by microsatellite instability. The complete remission rate was higher among patients with tumors without microsatellite instability (five of seven patients). Conclusion: In contrast to the limited efficacy of treatment with paclitaxel in combination with standard platinum doses against wild-type p53 ovarian tumors, patients with mutant p53 ovarian tumors were more responsive to paclitaxel-based chemotherapy. The pattern of response to chemotherapy containing paclitaxel is different from that associated with high-dose cisplatin therapy. Determining p53 mutational status can be useful in predicting therapeutic response to drugs effective in ovarian carcinoma.

Original languageEnglish
Pages (from-to)3936-3945
Number of pages10
JournalJournal of Clinical Oncology
Volume18
Issue number23
Publication statusPublished - Dec 1 2000

Fingerprint

p53 Genes
Paclitaxel
Platinum
Carcinoma
Drug Therapy
Neoplasms
Microsatellite Instability
Platinum Compounds
Taxoids
Therapeutics
Cisplatin
DNA Damage
Sequence Analysis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lavarino, C., Pilotti, S., Oggionni, M., Gatti, L., Perego, P., Bresciani, G., ... Zunino, F. (2000). p53 Gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. Journal of Clinical Oncology, 18(23), 3936-3945.

p53 Gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. / Lavarino, C.; Pilotti, S.; Oggionni, M.; Gatti, L.; Perego, P.; Bresciani, G.; Pierotti, M. A.; Scambia, G.; Ferrandina, G.; Fagotti, A.; Mangioni, C.; Lucchini, V.; Vecchione, F.; Bolis, G.; Scarfone, G.; Zunino, F.

In: Journal of Clinical Oncology, Vol. 18, No. 23, 01.12.2000, p. 3936-3945.

Research output: Contribution to journalArticle

Lavarino, C, Pilotti, S, Oggionni, M, Gatti, L, Perego, P, Bresciani, G, Pierotti, MA, Scambia, G, Ferrandina, G, Fagotti, A, Mangioni, C, Lucchini, V, Vecchione, F, Bolis, G, Scarfone, G & Zunino, F 2000, 'p53 Gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma', Journal of Clinical Oncology, vol. 18, no. 23, pp. 3936-3945.
Lavarino, C. ; Pilotti, S. ; Oggionni, M. ; Gatti, L. ; Perego, P. ; Bresciani, G. ; Pierotti, M. A. ; Scambia, G. ; Ferrandina, G. ; Fagotti, A. ; Mangioni, C. ; Lucchini, V. ; Vecchione, F. ; Bolis, G. ; Scarfone, G. ; Zunino, F. / p53 Gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. In: Journal of Clinical Oncology. 2000 ; Vol. 18, No. 23. pp. 3936-3945.
@article{47b471744cc34deab0b3d33b1371070f,
title = "p53 Gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma",
abstract = "Purpose: The p53 gene plays a critical role in cellular response to DNA damage and has been implicated in the response to platinum compounds in ovarian carcinoma patients. Because taxanes could induce p53-independent apoptosis, we assessed the relevance of p53 gene status to response in ovarian carcinoma patients receiving paclitaxel and platinum-containing chemotherapy. Patients and Methods: Forty-eight previously untreated patients with advanced disease received standard paclitaxel/platinum-based chemotherapy. In tumor specimens collected at the time of initial surgery, before therapy, p53 gene status and expression were examined by single-strand conformation polymorphism, sequence analysis, and immunohistochemical analysis. Microsatellite instability analysis was performed on available samples from 30 patients. Results: Thirty-four (71{\%}) of the 48 patients had a clinical response. Pathologic complete remission was documented in 13 (27{\%}) of 48 patients. p53 mutations were detected in 29 (60{\%}) of 48 tumors. Among the patients with mutant p53 tumors, 25 patients (86{\%}) responded to chemotherapy. Only nine (47{\%}) of 19 patients with wild-type p53 tumors responded to the same treatment. The overall response rate and the complete remission rate were significantly higher among patients with mutant p53 tumors than among patients with wild-type p53 tumors (P = .008). Most of the tested tumors not associated with complete remission (10 of 12 tumors) were also characterized by microsatellite instability. The complete remission rate was higher among patients with tumors without microsatellite instability (five of seven patients). Conclusion: In contrast to the limited efficacy of treatment with paclitaxel in combination with standard platinum doses against wild-type p53 ovarian tumors, patients with mutant p53 ovarian tumors were more responsive to paclitaxel-based chemotherapy. The pattern of response to chemotherapy containing paclitaxel is different from that associated with high-dose cisplatin therapy. Determining p53 mutational status can be useful in predicting therapeutic response to drugs effective in ovarian carcinoma.",
author = "C. Lavarino and S. Pilotti and M. Oggionni and L. Gatti and P. Perego and G. Bresciani and Pierotti, {M. A.} and G. Scambia and G. Ferrandina and A. Fagotti and C. Mangioni and V. Lucchini and F. Vecchione and G. Bolis and G. Scarfone and F. Zunino",
year = "2000",
month = "12",
day = "1",
language = "English",
volume = "18",
pages = "3936--3945",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "23",

}

TY - JOUR

T1 - p53 Gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma

AU - Lavarino, C.

AU - Pilotti, S.

AU - Oggionni, M.

AU - Gatti, L.

AU - Perego, P.

AU - Bresciani, G.

AU - Pierotti, M. A.

AU - Scambia, G.

AU - Ferrandina, G.

AU - Fagotti, A.

AU - Mangioni, C.

AU - Lucchini, V.

AU - Vecchione, F.

AU - Bolis, G.

AU - Scarfone, G.

AU - Zunino, F.

PY - 2000/12/1

Y1 - 2000/12/1

N2 - Purpose: The p53 gene plays a critical role in cellular response to DNA damage and has been implicated in the response to platinum compounds in ovarian carcinoma patients. Because taxanes could induce p53-independent apoptosis, we assessed the relevance of p53 gene status to response in ovarian carcinoma patients receiving paclitaxel and platinum-containing chemotherapy. Patients and Methods: Forty-eight previously untreated patients with advanced disease received standard paclitaxel/platinum-based chemotherapy. In tumor specimens collected at the time of initial surgery, before therapy, p53 gene status and expression were examined by single-strand conformation polymorphism, sequence analysis, and immunohistochemical analysis. Microsatellite instability analysis was performed on available samples from 30 patients. Results: Thirty-four (71%) of the 48 patients had a clinical response. Pathologic complete remission was documented in 13 (27%) of 48 patients. p53 mutations were detected in 29 (60%) of 48 tumors. Among the patients with mutant p53 tumors, 25 patients (86%) responded to chemotherapy. Only nine (47%) of 19 patients with wild-type p53 tumors responded to the same treatment. The overall response rate and the complete remission rate were significantly higher among patients with mutant p53 tumors than among patients with wild-type p53 tumors (P = .008). Most of the tested tumors not associated with complete remission (10 of 12 tumors) were also characterized by microsatellite instability. The complete remission rate was higher among patients with tumors without microsatellite instability (five of seven patients). Conclusion: In contrast to the limited efficacy of treatment with paclitaxel in combination with standard platinum doses against wild-type p53 ovarian tumors, patients with mutant p53 ovarian tumors were more responsive to paclitaxel-based chemotherapy. The pattern of response to chemotherapy containing paclitaxel is different from that associated with high-dose cisplatin therapy. Determining p53 mutational status can be useful in predicting therapeutic response to drugs effective in ovarian carcinoma.

AB - Purpose: The p53 gene plays a critical role in cellular response to DNA damage and has been implicated in the response to platinum compounds in ovarian carcinoma patients. Because taxanes could induce p53-independent apoptosis, we assessed the relevance of p53 gene status to response in ovarian carcinoma patients receiving paclitaxel and platinum-containing chemotherapy. Patients and Methods: Forty-eight previously untreated patients with advanced disease received standard paclitaxel/platinum-based chemotherapy. In tumor specimens collected at the time of initial surgery, before therapy, p53 gene status and expression were examined by single-strand conformation polymorphism, sequence analysis, and immunohistochemical analysis. Microsatellite instability analysis was performed on available samples from 30 patients. Results: Thirty-four (71%) of the 48 patients had a clinical response. Pathologic complete remission was documented in 13 (27%) of 48 patients. p53 mutations were detected in 29 (60%) of 48 tumors. Among the patients with mutant p53 tumors, 25 patients (86%) responded to chemotherapy. Only nine (47%) of 19 patients with wild-type p53 tumors responded to the same treatment. The overall response rate and the complete remission rate were significantly higher among patients with mutant p53 tumors than among patients with wild-type p53 tumors (P = .008). Most of the tested tumors not associated with complete remission (10 of 12 tumors) were also characterized by microsatellite instability. The complete remission rate was higher among patients with tumors without microsatellite instability (five of seven patients). Conclusion: In contrast to the limited efficacy of treatment with paclitaxel in combination with standard platinum doses against wild-type p53 ovarian tumors, patients with mutant p53 ovarian tumors were more responsive to paclitaxel-based chemotherapy. The pattern of response to chemotherapy containing paclitaxel is different from that associated with high-dose cisplatin therapy. Determining p53 mutational status can be useful in predicting therapeutic response to drugs effective in ovarian carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0034551724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034551724&partnerID=8YFLogxK

M3 - Article

C2 - 11099323

AN - SCOPUS:0034551724

VL - 18

SP - 3936

EP - 3945

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 23

ER -